54 citations,
September 2019 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.
20 citations,
June 2019 in “Journal of The European Academy of Dermatology and Venereology” Minoxidil effectively and safely treats patchy hair loss, but more research needed.
19 citations,
July 2019 in “Journal of Cosmetic Dermatology” A new tool can predict hair regrowth in patchy alopecia areata patients.
April 2021 in “Research Square (Research Square)” Achieving 80% or more scalp hair regrowth is considered a successful treatment for significant hair loss.
January 2022 in “Przegla̧d dermatologiczny” Platelet-rich plasma treatment can effectively promote hair regrowth in men with androgenetic alopecia without major side effects.
9 citations,
December 2020 in “Journal of The American Academy of Dermatology” Platelet-rich plasma may help restore immune balance in bald patches, but its effectiveness in treating hair loss is limited.
September 2024 in “Journal of the American Academy of Dermatology” Continued baricitinib treatment leads to significant scalp hair regrowth in severe alopecia areata patients.
11 citations,
May 2017 in “Journal of The European Academy of Dermatology and Venereology” Scalp threading with polydioxanone threads is a promising, effective, and safe method for hair regrowth.
2 citations,
February 2014 in “Hair therapy & transplantation” Alopecia Areata is an autoimmune condition causing hair loss, influenced by genetics, environment, and possibly improved by anti-MIF therapy, with many patients experiencing regrowth within a year.
28 citations,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
6 citations,
February 2021 in “Advances in Clinical and Experimental Medicine” Wharton's jelly-derived stem cells were safely used to treat four alopecia patients, resulting in hair regrowth in all of them.
2 citations,
September 2022 in “Dermatologic Therapy” Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib maintains significant hair regrowth in severe alopecia areata over three years.
September 2023 in “Journal of The American Academy of Dermatology” Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.
September 2024 in “Journal of the American Academy of Dermatology” Low-dose oral minoxidil helps hair regrowth in COVID-19-related hair loss with few side effects.
Current treatments for alopecia areata often fail to achieve and maintain significant hair regrowth.
10 citations,
September 2014 in “European Journal of Dermatology” A woman's hair loss worsened after starting hepatitis C treatment due to immune changes in her hair follicles.
September 2024 in “Journal of the American Academy of Dermatology” Microneedling mildly regrows hair in androgenetic alopecia but not in other types.
Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.
Reducing the dose of Baricitinib to 2mg still helped over half of the patients with severe scalp alopecia maintain their hair regrowth after two years.
3 citations,
October 2013 in “Photodermatology Photoimmunology & Photomedicine” The treatment is a safe and effective option for hair regrowth in patchy alopecia areata.
April 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” Topical gabapentin was safe and effective for treating scalp symptoms and promoting hair regrowth in cicatricial alopecias.
4 citations,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
August 2018 in “Journal of the American Academy of Dermatology” Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.
1 citations,
February 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively promotes long-term hair regrowth in alopecia areata patients.
10 citations,
January 2007 in “Journal of cosmetic and laser therapy” The IPL device is safe, effective, and has high patient satisfaction for hair removal.
Topical calcipotriol successfully treated hair loss in three patients with Alopecia Totalis.
48 citations,
February 2018 in “Journal of the American Academy of Dermatology” Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
2 citations,
July 2022 in “JAAD Case Reports” A woman lost all her hair after mild COVID-19, but it started to regrow after treatment with a specific medication.
September 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.